Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular C. Venkata S. Ram Texas Blood Pressure Institute, Dallas, TX; MediCiti Medical College/Hospitals, Hyderabad/India None None None None None None None Denise Simons-Morton NHLBI None None None None None None None Robert C. Touchon University Physicians and Surgeons, Joan C. Edwards School of Medicine, Marshall University, Huntington, WV None None None None None None None Thad F. Waites Hattiesburg Clinic, Hattiesburg, MS None None None None None None None Howard S. Weintraub New York University Medical Center None None AstraZeneca ; Daiichi Sankyo*; Takeda ; Abbott ; Kowa*; Novartis None None None None This table represents the relationships of reviewers that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all reviewers are required to complete and submit. A relationship is considered to be significant if (a) the person receives $10000 or more during any 12-month period, or 5% or more of the person s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $10000 or more of the fair market value of the entity. A relationship is considered to be modest if it is less than significant under the preceding definition. *Modest. Significant. Reviewer Disclosures, Continued Reviewer Employment Research Grant Other Research Support Speakers Bureau/Honoraria Expert Witness Ownership Interest Consultant/ Advisory Board Other events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145 153. 17. 